"Toll-Like Receptor 4" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pattern recognition receptor that interacts with LYMPHOCYTE ANTIGEN 96 and LIPOPOLYSACCHARIDES. It mediates cellular responses to GRAM-NEGATIVE BACTERIA.
| Descriptor ID |
D051197
|
| MeSH Number(s) |
D12.776.543.750.705.910.500.400
|
| Concept/Terms |
Toll-Like Receptor 4- Toll-Like Receptor 4
- Toll Like Receptor 4
- Toll-4 Receptor
- Toll 4 Receptor
- TLR4 Receptor
- Receptor, TLR4
|
Below are MeSH descriptors whose meaning is more general than "Toll-Like Receptor 4".
Below are MeSH descriptors whose meaning is more specific than "Toll-Like Receptor 4".
This graph shows the total number of publications written about "Toll-Like Receptor 4" by people in this website by year, and whether "Toll-Like Receptor 4" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 1 | 2 |
| 2006 | 2 | 1 | 3 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 3 | 4 |
| 2012 | 2 | 0 | 2 |
| 2013 | 1 | 1 | 2 |
| 2014 | 2 | 0 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 2 | 0 | 2 |
| 2019 | 1 | 2 | 3 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2024 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Toll-Like Receptor 4" by people in Profiles.
-
Alugupalli KR. Characterization of Turbo, a TLR Ligand-based Adjuvant for Glycoconjugate Vaccines. Immunohorizons. 2024 08 01; 8(8):527-537.
-
Alugupalli KR. A TLR4 ligand-based adjuvant for promoting the immunogenicity of typhoid subunit vaccines. Front Immunol. 2024; 15:1383476.
-
Alugupalli KR. Monophosphoryl Lipid A-based Adjuvant to Promote the Immunogenicity of Multivalent Meningococcal Polysaccharide Conjugate Vaccines. Immunohorizons. 2024 04 01; 8(4):317-325.
-
Alugupalli KR. TLR4 Ligands in Typhoid Vi Polysaccharide Subunit Vaccines Contribute to Immunogenicity. Immunohorizons. 2024 01 01; 8(1):29-34.
-
Palatnik-de-Sousa I, Wallace ZS, Cavalcante SC, Ribeiro MPF, Silva JABM, Cavalcante RC, Scheuermann RH, Palatnik-de-Sousa CB. A novel vaccine based on SARS-CoV-2 CD4+ and CD8+ T cell conserved epitopes from variants Alpha to Omicron. Sci Rep. 2022 10 06; 12(1):16731.
-
Shukur W, Alyaqubi K, Dosh R, Al-Ameri A, Al-Aubaidy H, Al-Maliki R, Aridhee A, Al-Fatlawi R, Hadi N. Association of Toll-like receptors 4 (TLR-4) gene expression and polymorphisms in patients with severe asthma. J Med Life. 2021 Jul-Aug; 14(4):544-548.
-
Novak T, Hall MW, McDonald DR, Newhams MM, Mistry AJ, Panoskaltsis-Mortari A, Mourani PM, Loftis LL, Weiss SL, Tarquinio KM, Markovitz B, Hartman ME, Schwarz A, Junger WG, Randolph AG. RIG-I and TLR4 responses and adverse outcomes in pediatric influenza-related critical illness. J Allergy Clin Immunol. 2020 06; 145(6):1673-1680.e11.
-
Portou MJ, Yu R, Baker D, Xu S, Abraham D, Tsui J. Hyperglycaemia and Ischaemia Impair Wound Healing via Toll-like Receptor 4 Pathway Activation in vitro and in an Experimental Murine Model. Eur J Vasc Endovasc Surg. 2020 Jan; 59(1):117-127.
-
Dombkowski AA, Cukovic D, Bagla S, Jones M, Caruso JA, Chugani HT, Chugani DC. TLR7 activation in epilepsy of tuberous sclerosis complex. Inflamm Res. 2019 Dec; 68(12):993-998.
-
Poluzzi C, Nastase MV, Zeng-Brouwers J, Roedig H, Hsieh LT, Michaelis JB, Buhl EM, Rezende F, Manavski Y, Bleich A, Boor P, Brandes RP, Pfeilschifter J, Stelzer EHK, M?nch C, Dikic I, Brandts C, Iozzo RV, Wygrecka M, Schaefer L. Biglycan evokes autophagy in macrophages via a?novel CD44/Toll-like receptor 4 signaling axis?in?ischemia/reperfusion injury. Kidney Int. 2019 03; 95(3):540-562.